Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAD vs VCD in Previously Untreated Multiple Myeloma
NCT01868828Phase 4Unknown
- Sponsor
- Peking University People's Hospital
- Start
- May 2013
- Primary completion
- May 2015
- Modality
- DNA Intercalators/Alkylators, Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of bortezomib, epirubicin, cyclophosphamide, dexamethasone in multiple myeloma (MM), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
bortezomibepirubicincyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01868828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01868828.